Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Celsion Corporation (CLSN) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

Celsion Corporation (CLSN)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: AVXL, EGRX, ZIOP, NBIX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: D down downgrade
Last Week: C same no change
Two Weeks Ago: C up upgrade
service keys

Celsion Corporation© quotemedia

Company Profile

Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; a license agreement with Duke University to commercialize and use Duke's thermo-liposome technology; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Recent News: Celsion Corporation